Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3720_Библиотеки_им_академика_М_И_Перельмана
.pdf
List of Contributors xxiii
https://t.me/med1917
Neil P. Lewis, MD, PhD, FACC
Medical Director Heart Failure
MCS, Transplantation
Department Cardiology
McGuire Veterans Affairs Medical Center
Richmond, VA, United States;
Professor of Medicine
Virginia Commonwealth University
School of Medicine
Richmond, VA, United States
Jurgen Ligthart
Erasmus University Rotterdam
Rotterdam, The Netherlands
Michael Lishner, MD
Professor of Medicine
Sackler Faculty of Medicine
Tel Aviv University
Head, Research Institute
Head, Department of Medicine A
Meir Medical Center
Kfar Saba, Israel
Alejandro E. Macias, MS
Division of Cardiothoracic Surgery and
the Miami Transplant Institute
University of Miami Miller School of Medicine and
Jackson Memorial Hospital
Michael Magarakis, MD
Division of Cardiothoracic Surgery and
the Miami Transplant Institute
University of Miami Miller School of Medicine and
Jackson Memorial Hospital
Miami, Florida, United State s
Ahmed N. Mahmoud, MD
Department of Medicine
Division of Cardiovascular Medicine
University of Florida
Gainesville, FL, United States
Dhruv Mahtta, MD, MBA
Department of Medicine
University of Florida
Gainesville, FL, United States
Anit Mankad, MD
Assistant Professor of Medicine, Virginia Commonwealth
University Health System
Richmond, VA, United States;
Transplant Cardiologist, Hunter Holmes McGuire VA
Medical Center
Richmond, VA, United States
Claudia A. Martinez, MD, FACC
Division of Cardiology
University of Miami Medical Center
Associate Professor Clinical Medicine
University of Miami Miller School of Medicine
Miami, FL, United States
Rodrigo Mendirichaga, MD
Section of Cardiovascular Medicine
Boston Medical Center, Boston University School of
Medicine
Boston, MA, United States
Elizabeth Michalets, PharmD, BCPS, FCCP
Mission Health System and the University of North
Carolina Eshelman School of Pharmacy
Manager, Pharmacy Education and Research
Professor of Clinical Education
Asheville, NC, United States
Benjamin Michalove, PharmD, CPP
PGY1 Pharmacy Residency Program Director
Clinical Pharmacy Specialist
Charles George Veterans Affairs Medical Center
Asheville, NC, United States
Subhashis Mitra, MD
Assistant Professor
Department of Medicine
Michigan State University
East Lansing, MI, United States
Srikanth Nagalla, MBBS, MS
Associate Professor of Medicine
Program Director, Hematology/Oncology Fellowship
Division of Hematology/Oncology
UT Southwestern Medical Center
Dallas, TX, United State s
Massimo Napodano, MD, PhD
Interventional Cardiology
Department of Cardiac
Thoracic and Vascular Sciences
University of Padova
Padova, Italy
Peter O’Kane, BSc, MBBS, MD, FRCP
Consultant Interventional Cardiologist
Dorset Heart Centre
Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom

xxiv List of Contributors
https://t.me/med1917
Takayuki Onishi, MD, FACC
Interventional Cardiologist
Department of Cardiology
Hiratsuka Kyosai Hospital
Hiratsuka, Kanagawa, Japan
Yuko Onishi, MD, FACC
Director, Department of Cardiology
Hiratsuka Kyosai Hospital
Hiratsuka, Kanagawa, Japan
Amir Orlev, MD
Barts Health NHS Trust
London, United Kingdom
Ada M. Palmisano, PhD
Department of Applied Mathematics and Statistics
Colorado School of Mines
Golden, Colorado, United States
Gabriella Passacquale, MD, PhD
Clinical Lecturer
Clinical Pharmacology
Cardiovascular Division
King’s College London
London, United Kingdom
Brian T. Peek, PharmD
Chief of Pharmacy
Coordinator Research and Development
Charles George Veterans
Affairs Medical Center
Asheville, NC, United States;
Clinical Associate Professor of Pharmacy Practice
Wingate University School of Pharmacy
Wingate, NC, United States
Divaka Perera, MD, FRCP
Consultant Cardiologist
Department of Cardiology
Guy’s & St. Thomas’ Hospital
London, United Kingdom
Krishnaraj S. Rathod, MRCP
Department of Cardiology
Barts Health NHS Trust
London, United Kingdom;
NIHR Cardiovascular Biomedical Research Cen tre
Barts Heart Centre
London, United Kingdom
Evelyn Regar, MD, PhD
University Hospital Zurich
Zürich, Switzerland
Claire Ren, MD
Erasmus University Rotterdam
Rotterdam, The Netherlands
British Heart Foundation Clinical Research Fellow
King’s College London
London, UK
Uri Rosenschein, MD, MBA, FACC, FESC, FSCAI
Chief, Department of Car diology
Bnai Zion Medical Center
Professor of Medicine
Technion Medical School
Haifa, Israel
Matthew J. Ryan, BSc (Hons), MBChB, MRCP
British Heart Foundation Clinical
Research Fellow, King’s College London
London, United Kingdom
Negar Salehi, MD
Michigan State University
East Lansing, MI, United States
Tomas A. Salerno, MD, FACC, FSTS, FACS
Division of Cardiothoracic Surgery and
The Miami Transplant Institute
Professor of Surgery
University of Miami Miller School of Medicine and
Jackson Memorial Hospital
Miami, FL, United States
Andres M. Pineda, MD, FACC
Cardiac Catheterization Laboratory
University of Florida College of Medicine e Jacksonville
Division of Cardiology
Jacksonville, FL, United States
Sunil V. Rao, MD, FACC, FACP, FSCAI
Professor of Medicine
Duke University Medical Center
Section Chief, Cardiology
Durham Veterans Affairs Medical Center
NC, United States
Satinder K. Sandhu, MD, FACC, FACP
Clinical Professor, Pediatrics
Director, Pediatric Cardiac Cath Lab
Director, Adult Congenital Heart Disease
University of Miami, Miller School of Medicine & Jackson
Memorial Hospital
Miami, FL, United States

List of Contributors xxv
https://t.me/med1917
Ian J. Sarembock, MB, ChB, MD, FACC, FSCAI
Medical Director, Valve & Structural Heart
Disease Division
Harold C. Schott Foundation
Endowed Chair in Structural Heart
The Christ Hospital Health Network & Lindner Center for
Research and Education
Cincinnati, OH, United States
Edward J. Sawey, MD
Fellow, Division of Cardiology
Virginia Commonwealth University
Richmond, VA, United States;
Hunter Holmes McGuire VA Medical Center
Richmond, VA, United States
Amit Segev, MD, FACC, FSCAI, FESC
Professor of Medicine
Sackler School of Medicine
Tel Aviv University, Israel
Head, Cardiovascular Institution
Leviev Heart Center
Sheba Medical Center
Tel Hashomer, Israel
Nicolas W. Shammas, MD, MS, EJD, FACC, FSCAI
Adjunct Clinical Associate Professor
Internal Medicine
University of Iowa Hospitals and Clinics
Davenport, IA, United States;
Research Director and Founder
Midwest Cardiovascular Research Foundation
Davenport, IA, United States
Yu-Min Shen, MD
Associate Professor of Medicine
Division of Hematology/Oncology
UT Southwestern Medical Center
Dallas, TX, United States
Arthur Shiyovich, MD, FACC
Department of Cardiology
Institute of Interventional Cardiology
Rabin Medical Center
Petach Tikva, Israel;
Sackler Faculty of Medicine
Tel Aviv University
Tel Aviv, Israel
Satya S. Shreenivas, MD, FACC
Division of Interventional Cardiology
Division of Valve and Structural Heart
The Christ Hospital Heart and Vascular Center and
The Lindner Center for Research and Education
Cincinnati, OH, United States
James Smith, MD, FACC, FSCAI
Division of Cardiology
Wake Forest Baptist Health
Winston-Salem, NC, United States
Elliot J. Smith, MD, FRCP
Department of Cardiology
Barts Health NHS Trust
London, United Kingdom;
NIHR Cardiovascular Biomedical Research Centre
Barts Heart Centre
London, United Kingdom
Emily Stumpf, DO
Division of Pediatric Cardiology
Jackson Memorial Hospital
Miami, Florida, United States
Allyne Topaz, MD
Surgical Resident, PG-4,
Department of Surgery
Brooklyn Medical Center
Brooklyn, NY, United States
Imre Ungi, MD
Division of Invasive Car diology
Second Department of Internal Medicine and
Cardiology Center
University of Szeged
Szeged, Hungary
Avraham Unterman, MD, MBA
Pulmonologist, Pulmonary Division
Rabin Medical Center
Beilinson Campus, Petah Tikva, Israel;
Sackler Faculty of Medicine
Tel Aviv University
Tel Aviv, Israel
Gemma Vilahur, PhD, FESC
Senior Researcher
Cardiovascular Program ICCC
Institut de Recerca
Hospital de la Santa Creu i Sant Pau
IIB-Sant Pau, Barcelona;
CIBERCV-ISCIII, Madrid, Spain
Renu Virmani, MD, FACC, FACP
Professor of Pathology
Georgetown University - School of Medicine
Washington D.C.
Medical Director/President
CVPath Institute, Inc.
Gaithersburg, United States

xxvi List of Contributors
https://t.me/med1917
Thomas E. Watts, MD, FACC
Division of Cardiovascular Disease
University of Alabama at Birmingham
Birmingham, AL, United States
Emily E. Wood, PharmD
Clinical Pharmacy Specialist
Charles George Veterans Affairs Medical Center
Asheville, NC, United States;
Adjunct Faculty Member
Mercer University College of Pharmacy
Atlanta, GA, United States
Arwa Younis, MD, FACC
Department of Cardiology
The Leviev Heart Center
Sheba Medical Center and Sackler School of Medicine
Tel Aviv University Ramat Gan, Israel
Richard L. Zampolin, MD
Division of Radiology
Montefiore Medical Center
Albert Einstein School of Medicine
Bronx, NY, United States

Foreword
https://t.me/med1917
It gives me great pleasure to contribute the foreword for the first edition of this splendid book by Dr. On Topaz,
Professor of Medicine, Duke University School of Medicine, and Chief, Division of Cardiology, Charles George Veterans
Affairs Medical Center, Asheville, North Carolina, entitled Cardiovascular Thrombus: From Pathology and Clinical
Presentation to Imaging, Pharmacotherapy, and Interventions, by the publisher Elsevier.
There is no doubt about the importance of thrombosis in medicine today. It serves in clinical medicine as an
important growth area of research and clinical activities, as well as a major topic involving a multidisciplinary group
approach that includes internal medicine, hematology, radiolo gy, gen e ral ca r diolo gy, interventional cardiology, and
cardiac surgery. Although the role of throm bo si s leading to both chronic car dio vasc ul ar disease and acute lifethreatening complications has been recognized for many years, clinical developments in recent years have helped to
illuminate the pathophysiological changes affecting both thrombosis and thrombolysis, as well as our ability to diagnose
and modify these processes.
This book provides a comprehensive, contemporary source of research and clinical practice related to the current
aspects of the diagnosis and management of cardiovascular thrombosis. It is well known that the hemostatic system
serves to maintain a delicate balance between the processes of coagulation and anticoagulation, platelet activation and
inhibition, and activation and inhibition of fibrinolysis to ensure vascular patency. Abnormalities in these processes can
precipitate hemorrhage or arterial and venous thrombosis. Acute thrombotic e vents characterize common clinical
manifestations of cardiovascular disease, including acute coronary syndrome, myocardial infarction, and ischemic
stroke. Antithrombotic interventions, such as aspirin, platelet receptor inhibitors, P2Y12 inhibitors, and thrombolytic
agents, underpin the management of cardiovascular disease, highlighting the critical role of thrombosis in cardiovascular
morbidity and mortality.
This book has been published at a most opportune time. It is among the first books yet written on this important subject,
and I believe it is among the more ambitious and best productions on this topic. It is designed to help physicians in all
specialties as they apply recent information about thrombosis, the coagulation system, and cardiovascular diseases. The
editor and the contributing authors are highly respected world leaders in this field and their background, personal
contributions, and deep knowledge of the subject complement one a nother remarkably. At the same time, the book is
intensely practical, thus bringing the unique knowledge and insights of the contributing authors and the editor to bear on
the interpretation of the experimental and clinical observations in this rapidly expanding field.
Cardiovascular thrombus is of paramount importance for researchers and practicing physicians, yet it remains
among the most challenging diagnosti c and clinical scenarios. This important refer en ce book bridg es the gap
between research, up-to-da te clinical information, and the technological facets of thrombus formation, di ag nos is, and
management in c ar diov ascu la r medicine. The book includes complete coverage of pathology, clinical presentation s,
diagnosis, pharmacotherapy , interventions, and future trends set in a comprehensive, up-to-date format. Furthermore,
this book also considers the potential future ap plica ti on s of various technologies in furt heri ng our understanding of
the mechanisms contributing to formation of cardiovascular thrombus and to thrombus resolution, which may
ultimately lead to the identification of additional therapeutic pathways that could be targeted for development of new
antithrombotic therapies.
I would like to congratulate Dr. On Topaz and his excellent group of distinguished contributing authors who
accomplished in each chapter of this book the indispensable concepts required to approach critical diagnostic and
therapeutic needs in clinical cardiovascular medicine. The introduction of newer techniques for the diagnosis and treatment
of thrombotic cardiovascular disease has changed considerably the diagnostic and therapeutic scenarios. The recent
advances in the study of thrombosis have altered permanently the management of patients with cardiovascular disease as
well as healthy persons who are at risk for development of cardiovascular thrombotic diseases.
xxvii

xxviii Foreword
https://t.me/med1917
Finally, I wish that all readers of this book enjoy and use it as a beneficial tool as much as I myself did. I believe that
this textbook will prove invaluable to all researchers and investigators of thromboembolic disorders, as well as to
noninvasive cardiologists, interventional cardiologists and radiologists, vascular and cardiovascular surgeons, internists,
hematologists, vascular medicine specialists, pharmacists, and medical students, all of whom wish to consider choices and
make informed clinical decisions when dealing with cardiovascular thrombus and thromboembolic problems in their daily
practice.
Igor F. Palacios, MD, FACC, FACP, FSCAI
Director of Interventional Cardiology
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Preface
https://t.me/med1917
The extraordinary work of art on the book’s cover illustrates dramatically the ominous threat thrombus imposes on the
heart and great vessels and, by implication, the entire cardiovascular system and lif e. This painting on canvas by the artists
Scott Meskill and Shannon Donnelly reflects their visual interpretation of thrombus and thrombosis while they were in
attendance at an Emergency Medicine conference. We chose to exhibit this painting as the gate opener to an all-inclusive
book, covering the full spectrum of cardiovascular thrombus.
My personal odyssey toward “all things thrombus ” was launched during fellowships training in cardiovascular
pathology, cardiology, and interventional cardiology. This education brought to light the prevalence and catastrophic
effects of cardiovascular thrombus as observed from the unique perspective of these intertwining disciplines. In the pathology suite, we studied hearts, vessels, organs, and accompanying thrombi in patients who had died from complications
attributed to cardiovascular thrombi, gaining a final view on the inflicted damage. Thus, clinically, I serve as a longstanding observer to the ubiquitous and rich clinical presentations of cardiovascular thrombi, while participating in the
development of dedicated management strategies and related technologies.
As clinicians, we constantlywitness and dealwith the tremendousinjury thrombi causepatients. Intriguingly, thrombusis an
essential component of hemostasis, yet its formation frequently serves as a harbinger of vascular complication or as a blatant
testimonial to an already existing cardiovascular damage. Thrombusis omnipresent in the arterial and venous circulation, inside
cardiac chambers, adhering to valves, lodging in the great vessels, and embolizingthroughthe vasculature to many organs.The
extraordinary pathology and complex morphologic features of different types of thrombi and related physical and rheolytic
properties are of significant interest to many. Indeed, thrombi are a study in biologic contradictions: some firmly attach to
structures and vessels while others float freely. Thrombi vary in age and often exhibit fresh layers interspersed with or
superimposed over oldlayers.A thrombus size can be anywherefrom microscopicto largedat times evenreachinga monstrous
length and shape. Thrombi are built of unique constituents and carry select signature receptors that excrete procoagulants and
vasoactive reactants, making them strongly susceptible to accumulation. The brittle and unstable nature of thrombi means
unpredictable clinical outcomes, thrombi are commonly resistant to extraction yet prone to embolization even if treated.
While writing the chapter “The Thrombus-Containing Lesion” for consecutive editions of the Textbook of Interven-
tional Cardiology, edited by Topol and Teirstein, Elsevier, I developed a growing interest in the potential of a new book
aimed at comprehensive coverage of contemporary research, clinical, diagnostic, manag ement, and therapeutic aspects of
cardiovascular thrombus. The publisher Elsevier readily agreed to embrace this quest, and I am grateful for the privilege of
editing this book. Accordingly, special thanks to Ms. Stacy Masucci, Senior Acquisitions Editor, Biomedical Research and
Reference, at Elsevier. Personal appreciation is expressed to Mr. Samuel Young, the book’s project manager. Ms. Arya
Dowis, 4th year medical student from the Edward Via College of Osteopathic Medicine, provided thoughtful academic
contributions to the book project which are highly appreciated. All along this project, here at the Charles George Veterans
Affairs Medical Center, the gifted Matt Holtz, BS, RCIS, provided outstanding technical support, excellent electronic
media preparation, and insightful advice.
Upon the publication of this book, I wish to express a deep gratitude to the distinguished contributing authors,
comprising scientists, researchers, and clinicians who responded affirmatively to my invitation, generously contributing
their time and talent. Consequen tly, the scientific data as published in this book represent an array of contemporary views
on multiple topics. The contributing authors and I trust that the readership, including students, scientists, and clinicians
alike, from the vast fields of medicine, will benefit from the teaching points and profound expertise and stands to find this
book a comprehensive and interesting resource.
Finally, our sincere wish is that this book will cultivate further research and lead to the development of new therapies.
May many patients around the world benefit from the knowledge gained by the readers.
On Topaz, MD
Asheville, NC, USA
xxix

https://t.me/med1917

2 Cardiovascular Thrombus
https://t.me/med1917
TABLE 1.1 Distribution of Culprit Plaques by Sex and Age in Sudden Coronary Death
No Acute Thrombi (Stable Severe
Acute Thrombi (n [ 236)
Calcified
Subpopulation
Men ages <50 years 82 (48%) 34 (20%) 3 (2%) 16 (9%) 36 (21%) 171
Men ages 50 years 59 (31%) 14 (7%) 6 (3%) 46 (24%) 63 (34%) 188
All men 141 (39%) 48 (13%) 9 (3%) 62 (17%) 99 (28%) 359
Women ages <50 years 3 (6%) 16 (36%) 0 (0%) 4 (9%) 21 (48%) 44
Women ages 50 years 10 (26%) 6 (15%) 3 (8%) 8 (21%) 12 (31%) 39
All women 13 (16%) 22 (27%) 3 (4%) 12 (14%) 33 (40%) 83
Total population 154 (35%) 70 (16%) 12 (3%) 74 (17%) 132 (30%) 442
Histological definition of CTO was defined as lumen area occupied by proteoglycan and /or collagen with or without neovascularization and chronic
inflammation.
Organized thrombi with healed myocardial infarction ¼ 62/74 (84%). No thrombi (stable plaque) with healed myocardial infarction ¼ 71/132 (54%).
CAD, coronary artery disease; CTO, chronic total occlusion.
Reprinted from Yahagi K, et al. Sex differences in coronary artery disease: pathological observations. Atherosclerosis 2015;239(1):260e7 © with
permission from Elsevier.
Nodule
Organized
Thrombi (CTO) No Thrombi
CAD) (n [ 206)
TotalRupture Erosion
Plaque Rupture
Plaque rupture is defined by the presence of a disrupted thin fibrous cap with overlying thrombus and an underlying
necrotic core. The underlying necrotic core in plaque rupture usually occupies >30% of the total plaque area [8e10]
(Fig. 1.1A). The thin fibrous cap is made up of type I collagen with very few smooth muscle cells interspersed, but is
infiltrated by varying numbers of macrophages and T lymphocytes. The mean fibrous cap thickness at the rupture site is
23 19 mm, and 95% of the fibrous caps are <64 mm [5]. The disrupted fibrous cap allows contact of flowing blood with
the highly thrombogenic necrotic core. This blood allows large numbers of platelets to be activated and aggregate at the
rupture site forming a white thrombus (Figs. 1.2 and 1.3). The thrombus may or may not lead to a complete obstruction of
the coronary lumen. If there is obstruction and a side branch is present proximal to the obstruction site, the thrombus
propagates to the side branch and consists of layers of fibrin (lines of Zahn) separated by red blood cells, classified as a red
thrombus. Eventually, if the thrombus is not removed or crushed by angioplasty or thrombolysis, it will organize by
infiltration of inflammatory cells, especially macrophages, releasing growth factors that attract endothelial cells and smooth
muscle cells, which proliferate and deposit extracellular matrix consisting of proteoglycans and collagen, leading to organization of the thrombus and chronic total occlusion of the coronary artery.
Ruptured plaques (PRs) are believed to be preceded by thin-cap fibroatheromas (TCFAs) , also called vulnerable
plaques, which are likely precursor lesions of PRs, except that the cap is intact and less than 65 mm, the necrotic core is
smaller, and the lesions are less calcified. We have reported on the radiographic appearance of calcium in ruptures,
erosions, and TCFAs. Calcification is greatest in ruptures, followed by TCFAs, and least in erosions [11]. With regard to
location of disruption of the fibrous cap in PRs, human autopsy studies have shown that rupture occurs not only at shoulder
regions but also at the midportion of the fibrous cap [12]. In addition, rupture at the thinnest, midportion of the fibrous cap
was associated with exercise [12]. Also, emotional stress has been reported to precipitate cardiac events [13]. Select
proteases secreted by macrophages possibly weaken the fibrous cap, and high shear and tensile stress all may be involved
in triggering rupture [14,15]. In addition, microcalcification (>5 mm) originating from dying macrophages or smooth
muscle cells has also been hypothesized to possibly trigger rupture, possibly due to increased stress that leads to interfacial
debonding [16,17].
In 1997, Burke et al. reported an association between serum lipid profile (total cholesterol, high-density lipoprotein
(HDL) cholesterol, ratio of total cholesterol to HDL), smoking (serum thiocyanate, a surrogate marker for smoking), and
plaque rupture in 113 men who died suddenly. Among them, 96.5% had one or more risk factors regardless of etiology of
coronary thrombus, with smoking being a predictor of acute thrombosis [18]. Plaque rupture was associated with high total
cholesterol, low HDL cholesterol, and elevated ratio of total to HDL cholesterol. In addition, patients who had high levels
of total cholesterol had a greater number of TCFAs. Diabetes was a predictor of stable plaque, as well as total and distal

Histopathology of Cardiovascular Thrombus Chapter | 1 3
https://t.me/med1917
(A) (B) (C) (D)
Rupture
Th
Underlying PIT
Th
Erosion
Underlying FA
Th
Th
NC
Th
Calcified nodule
Th
Smooth muscle cells
Macrophage foam cells
Extracellular lipid
Cholesterol clefts
Necrotic core
Calcified plaque
Nodular
++
NC
Ca
Collagen
Hemorrhage
Thrombus
Healed thrombus
Angiogenesis
Fibrin
FIGURE 1.1 Human coronary lesion morphologies categorized as “lesions with acute thrombi.” Histological and schematic images are shown for
(A) plaque rupture, (B) plaque erosion with underlying pathological intimal thickening (PIT), (C) plaque erosion with underlying fibroatheroma (FA), and
(D) calcified nodule. Arrowheads indicate fibrous cap. NC, necrotic core; Th, thrombus. Histological images in (A), (B), and (D) reprinted from Falk E,
Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J 2013;34(10):719e28 by
permission of Oxford University Press and the European Society of Cardiology. (C) Reprinted from Otsuka F, et al. Clinical classification of plaque
morphology in coronary disease. Nat Rev Cardiol 2014;11:379e89 with permission from Elsevier.
Thrombus Propagation in Plaque Rupture
(A)
1mm
(B)
Platelet-rich
thrombus
LD
LAD
Proximal fibrin-rich
propagated
thrombus
(D)
FIGURE 1.2 Thrombus propagation in plaque rupture. (A) Composition of a longitudinal section of the LAD coronary artery with plaque rupture; the
rupture site is marked by the arrowhead (Movat pentachrome, original magnification 20). (B) The same longitudinal section as in (A) stained with
Carstairs’ method for the detection of fibrin (dark red) and platelets (blue-gray). The proximal thrombus consists predominantly of fibrin with red cells
interspersed, while the distal portion of the rupture site is platelet rich. (C) Platelets were further confirmed using antibody directed against glycoprotein
IIIa. (D) Proximal propagated portion of the thrombus showing mostly fibrin and red cells; mild layered reactivity is seen for platelets. LD, left diagonal
branch; LAD, left anterior descending. Reproduced with permission from Virmani R, Narula J, Leon MB, Willerson JT, editors. The vulnerable
atherosclerotic plaque. Plaque Rupture. MA, USA: Blackwell Futura; 2007 [Chapter 3]. p. 53. Figure 3.15.
(C)
Carstairs
Platelets
Proximal
Propagated
Thrombus
,
Platelet
Fibrin
Соседние файлы в папке Библиотека им академика М.И. Перельмана
